Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses

Key Takeaways

• Tafluprost 0.0015% ophthalmic solution is FDA-approved to reduce elevated IOP in open-angle glaucoma or ocular hypertension (initial U.S. approval 2012).
• Recommended tafluprost dose: one drop in the affected eye(s) once daily in the evening; more frequent dosing may lessen effect.
• Tobramycin 0.3% ophthalmic solution is indicated for external infections of the eye and adnexa caused by susceptible bacteria.
• Sodium hyaluronate appears in many lubricating eye drops for dry eye symptom relief; it is not a substitute for labeled antibiotic or IOP therapies.

What is tafluprost used for on the eye drugs list?

Tafluprost ophthalmic solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, per DailyMed and the FDA label for Zioptan (DailyMed tafluprost; FDA label PDF).

Dose: one drop in the conjunctival sac of the affected eye(s) once daily in the evening. IOP reduction begins about 2–4 hours after the first dose, with maximum effect around 12 hours.

What is tobramycin ophthalmic solution indicated for?

Tobramycin ophthalmic solution 0.3% is a sterile topical antibiotic for external infections of the eye and its adnexa caused by susceptible bacteria (DailyMed tobramycin).

Typical labeled dosing: 1–2 drops every 4 hours for mild to moderate disease; for severe infections, 2 drops hourly until improvement, then taper. Bacterial response should be monitored.

Where does sodium hyaluronate fit?

Sodium hyaluronate (hyaluronic acid) is widely used in lubricating artificial tears for dry-eye symptom relief. The National Eye Institute describes dry eye as a common condition managed with approaches that can include over-the-counter lubricating drops (NEI dry eye overview).

Lubricants do not treat bacterial keratitis or replace prostaglandin IOP therapy; keep indication classes separate on any formulary list.

What safety notes matter for BD and medical affairs?

Prostaglandin analogs can cause iris color change, eyelash growth, and macular edema risk factors noted in labels. Aminoglycoside ophthalmics can select resistant organisms and cause hypersensitivity; discontinue if sensitivity appears, per tobramycin labeling.

When multiple topical agents are used, separate administration by at least five minutes as labeled for tafluprost products.

What remains unproven?

This list does not rank comparative effectiveness among prostaglandin analogs or among antibiotic classes. Head-to-head share or EU reimbursement outcomes are outside the FDA/DailyMed sources cited here.

How should an eye drugs list be structured for formulary work?

Separate classes clearly: IOP-lowering prostaglandin analogs (tafluprost), topical antibiotics (tobramycin), and lubricating agents (often sodium hyaluronate–based tears). Mixing classes in a single undifferentiated “eye drop” bucket creates medical and commercial errors.

Label literacy matters. Tafluprost’s once-daily evening schedule and washout guidance when combining agents come from FDA prescribing information, not marketing copy. Tobramycin’s hourly-then-taper severe-infection schedule is similarly label-driven and should not be generalized to other antibiotic molecules without their own PI.

For EU readers, confirm local SmPC wording and reimbursement status separately; this article’s citations are FDA/DailyMed and NEI references used as primary evidence for U.S. labeled uses.

Related NovaPharma coverage

• Vabysmo EU RVO approval
• Areas with risk of dengue
• Breast cancer statistics worldwide

Frequently Asked Questions

Primary Sources

1. DailyMed: tafluprost ophthalmic solution
2. FDA: Zioptan (tafluprost) label
3. DailyMed: tobramycin ophthalmic solution
4. NEI: dry eye disease overview